KR100974842B1 - 아편양 길항제의 중합체 공액 - Google Patents

아편양 길항제의 중합체 공액 Download PDF

Info

Publication number
KR100974842B1
KR100974842B1 KR1020047005735A KR20047005735A KR100974842B1 KR 100974842 B1 KR100974842 B1 KR 100974842B1 KR 1020047005735 A KR1020047005735 A KR 1020047005735A KR 20047005735 A KR20047005735 A KR 20047005735A KR 100974842 B1 KR100974842 B1 KR 100974842B1
Authority
KR
South Korea
Prior art keywords
polymer
delete delete
opioid
conjugate
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047005735A
Other languages
English (en)
Korean (ko)
Other versions
KR20050037423A (ko
Inventor
마이클 데이비드 벤틀리
마이클 제임스 로버츠
샤오밍 센
린 쳉
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20050037423A publication Critical patent/KR20050037423A/ko
Application granted granted Critical
Publication of KR100974842B1 publication Critical patent/KR100974842B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020047005735A 2001-10-18 2002-10-18 아편양 길항제의 중합체 공액 Expired - Lifetime KR100974842B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33040001P 2001-10-18 2001-10-18
US60/330,400 2001-10-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097025168A Division KR101009309B1 (ko) 2001-10-18 2002-10-18 아편양 길항제의 중합체 공액

Publications (2)

Publication Number Publication Date
KR20050037423A KR20050037423A (ko) 2005-04-21
KR100974842B1 true KR100974842B1 (ko) 2010-08-11

Family

ID=23289594

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047005735A Expired - Lifetime KR100974842B1 (ko) 2001-10-18 2002-10-18 아편양 길항제의 중합체 공액
KR1020097025168A Expired - Lifetime KR101009309B1 (ko) 2001-10-18 2002-10-18 아편양 길항제의 중합체 공액

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097025168A Expired - Lifetime KR101009309B1 (ko) 2001-10-18 2002-10-18 아편양 길항제의 중합체 공액

Country Status (14)

Country Link
US (4) US7056500B2 (https=)
EP (3) EP2236161A1 (https=)
JP (2) JP4814488B2 (https=)
KR (2) KR100974842B1 (https=)
AU (1) AU2002360284B2 (https=)
CA (1) CA2463938C (https=)
CY (1) CY1119906T1 (https=)
DK (2) DK1436012T3 (https=)
ES (2) ES2654819T3 (https=)
LT (1) LT1436012T (https=)
MX (1) MXPA04003597A (https=)
PT (2) PT1436012T (https=)
SI (2) SI2939696T1 (https=)
WO (1) WO2003032990A2 (https=)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
MXPA02003176A (es) * 1999-10-04 2002-09-30 Shearwater Corp Neuropeptidos estabilizados por polimero.
ES2654819T3 (es) 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
EP1638607A1 (en) * 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
CA2811272C (en) * 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
EP1725572B1 (de) 2003-11-05 2017-05-31 AGCT GmbH Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
AU2014280956B2 (en) * 2003-12-16 2016-09-22 Nektar Therapeutics Chemically modified small molecules
WO2005058367A2 (en) * 2003-12-16 2005-06-30 Nektar Therapeutics Al, Corporation Pegylated small molecules
AU2005229001A1 (en) * 2004-03-23 2005-10-13 Amgen Inc. Chemically modified protein compositions and methods
AU2005254933B2 (en) * 2004-06-08 2010-08-19 Mallinckrodt Inc. Extraction of alkaloids from opium
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
ES2629766T3 (es) 2006-04-21 2017-08-14 Nektar Therapeutics Reducción estereoselectiva de una morfinona
MX2008014794A (es) 2006-05-26 2009-04-08 Pharmacofore Inc Liberacion controlada de opioides fenolicos.
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
AU2007317788B2 (en) * 2006-11-07 2013-05-02 Nektar Therapeutics Dosage forms and co-administration of an opioid agonist and an opioid antagonist
EP2101774A2 (en) * 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
US20110105381A2 (en) * 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
EP2134181A4 (en) * 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
AU2008226822B2 (en) * 2007-03-12 2013-08-01 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
JP2011519930A (ja) * 2008-05-07 2011-07-14 ネクター セラピューティクス 末梢性オピオイドアンタゴニストの経口投与
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
JP5827123B2 (ja) * 2008-09-16 2015-12-02 ウェルズ ファーゴ バンク ナショナル アソシエイション 乱用の可能性が低いｐｅｇ化オピオイド
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
EP2494073B1 (de) 2009-10-26 2017-11-29 AGCT GmbH Konjugate von nukleotiden und methoden zu deren anwendung
CN102918039B (zh) 2010-03-11 2017-06-09 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
PE20140636A1 (es) 2010-09-30 2014-06-18 Astrazeneca Ab Conjugado de naloxol-peg cristalino
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
EP2654795B1 (en) 2010-12-21 2018-03-07 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
MX348933B (es) * 2011-11-07 2017-07-03 Nektar Therapeutics Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
EP2895157A4 (en) * 2012-09-11 2016-07-13 Univ Massachusetts NETWORKED POLYMER NANOBAU GROUPS AND USES THEREOF
CN104755481A (zh) 2012-10-30 2015-07-01 尼克塔治疗公司 作为阿片激动剂的α-6-mPEG6-O-羟基可酮的固体盐形式以及其用途
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
PL3137081T3 (pl) * 2014-04-28 2018-06-29 Orphomed, Inc. Dimer buprenorfiny i jego zastosowanie w leczeniu chorób układu pokarmowego
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016064914A1 (en) * 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10226456B2 (en) * 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
WO2017041095A1 (en) 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
US11590241B2 (en) 2016-02-18 2023-02-28 Virginia Commonwealth University Nanoparticle conjugated synthetic opioid prodrugs and methods of their uses
CN108210933B (zh) * 2016-12-22 2021-05-04 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
US11254685B2 (en) 2017-07-20 2022-02-22 Suzhou Runxindatai Pharmaceutics Ltd Co. Abuse-resistant long-acting release opioid prodrugs
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
US12433883B2 (en) 2019-03-29 2025-10-07 Allegheny Singer Research Institute Covalent modification and controlled delivery of mu opioid receptor antagonists
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
IT202200026703A1 (it) 2022-12-23 2024-06-23 Sintalica S R L Composti triptamminici non allucinogeni, preparazione, composizioni farmaceutiche e relativi usi
WO2024227190A1 (en) * 2023-04-28 2024-10-31 Arizona Board Of Regents On Behalf Of The University Of Arizona Druggable formulation for mu/delta opioid antagonist for enhancing pain therapy and treatment of opioid withdrawal
WO2025029623A2 (en) * 2023-07-28 2025-02-06 The Children's Medical Center Corporation Light-triggered polymer-naloxone conjugate for opioid reversal

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021469A1 (en) 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1999045964A1 (en) 1998-03-12 1999-09-16 Shearwater Polymers, Incorporated Poly(ethylene glycol) derivatives with proximal reactive groups
WO2002092060A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (de) 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4864781A (en) * 1981-06-17 1989-09-12 Emblin Robert T Multiple panel metal roofing system with overlapping panel edges
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
FR2514644A1 (fr) 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
ES2104566T3 (es) * 1989-03-10 1997-10-16 Hoffmann La Roche Reactivos para la determinacion de drogas.
JPH0383914A (ja) * 1989-08-18 1991-04-09 W R Grace & Co ドラッグキャリアー
US5130126A (en) 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE69709646T2 (de) * 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
JP2001526228A (ja) * 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
DE60119696T2 (de) * 2000-03-15 2007-01-25 Wolfgang Ross Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
AU2002217981A1 (en) 2000-11-30 2002-06-11 Cornerstone Pharmaceuticals, Inc. Water-soluble polymer conjugates of triazine derivatives
ATE378342T1 (de) 2001-02-20 2007-11-15 Enzon Inc Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
ES2654819T3 (es) 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
EP1441772A2 (en) 2001-10-29 2004-08-04 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
ATE359829T1 (de) 2001-10-30 2007-05-15 Nektar Therapeutics Al Corp Wasserlösliche polymerkonjugate von retinoesäure
CA2822457C (en) 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP2006520392A (ja) 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
WO2005058367A2 (en) 2003-12-16 2005-06-30 Nektar Therapeutics Al, Corporation Pegylated small molecules
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
ES2629766T3 (es) 2006-04-21 2017-08-14 Nektar Therapeutics Reducción estereoselectiva de una morfinona
AU2007317788B2 (en) 2006-11-07 2013-05-02 Nektar Therapeutics Dosage forms and co-administration of an opioid agonist and an opioid antagonist
CA2699172C (en) * 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
KR102612902B1 (ko) 2016-04-22 2023-12-18 삼성디스플레이 주식회사 투명 전도막 및 이를 포함하는 전자 소자

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021469A1 (en) 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1999045964A1 (en) 1998-03-12 1999-09-16 Shearwater Polymers, Incorporated Poly(ethylene glycol) derivatives with proximal reactive groups
WO2002092060A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Controlled Release 16: 43-52 (1991)

Also Published As

Publication number Publication date
US7056500B2 (en) 2006-06-06
EP2236161A1 (en) 2010-10-06
SI1436012T1 (en) 2018-03-30
US8617530B2 (en) 2013-12-31
CY1119906T1 (el) 2018-06-27
ES2569262T3 (es) 2016-05-09
JP2005506351A (ja) 2005-03-03
SI2939696T1 (sl) 2016-06-30
EP2939696A1 (en) 2015-11-04
US20130165466A1 (en) 2013-06-27
AU2002360284B2 (en) 2006-11-02
WO2003032990A2 (en) 2003-04-24
PT2939696E (pt) 2016-06-17
JP4814488B2 (ja) 2011-11-16
DK1436012T3 (en) 2018-01-22
KR20090130155A (ko) 2009-12-17
MXPA04003597A (es) 2004-07-30
AU2002360284C1 (en) 2003-04-28
WO2003032990A3 (en) 2004-02-26
LT1436012T (lt) 2018-04-10
CA2463938A1 (en) 2003-04-24
US20060105046A1 (en) 2006-05-18
US20030124086A1 (en) 2003-07-03
US7662365B2 (en) 2010-02-16
PT1436012T (pt) 2018-03-27
HK1215171A1 (en) 2016-08-19
KR20050037423A (ko) 2005-04-21
EP1436012A2 (en) 2004-07-14
KR101009309B1 (ko) 2011-01-18
CA2463938C (en) 2011-08-09
EP2939696B1 (en) 2016-03-09
US8349307B2 (en) 2013-01-08
EP1436012B1 (en) 2017-12-20
DK2939696T3 (en) 2016-05-23
ES2654819T3 (es) 2018-02-15
JP2009167214A (ja) 2009-07-30
JP5570137B2 (ja) 2014-08-13
US20100105715A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
KR100974842B1 (ko) 아편양 길항제의 중합체 공액
AU2002360284A1 (en) Polymer conjugates of opioid antagonists
JP5827123B2 (ja) 乱用の可能性が低いｐｅｇ化オピオイド
ES2629696T3 (es) Profármacos poliméricos multibrazo
JP5837491B2 (ja) オリゴマー−オピオイドアゴニスト抱合体
EP1441772A2 (en) Polymer conjugates of protein kinase c inhibitors
AU2002342193A1 (en) Polymer conjugates of protein kinase C inhibitors
HK1147436A (en) Polymer conjugates of opioid antagonists
HK1215171B (en) Polymer conjugates of opioid antagonists
HK1156849A (en) Pegylated opioids with low potential for abuse
MXPA06003108A (en) Multi-arm polymer prodrugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040417

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070919

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090414

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090804

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090414

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20091104

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090804

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100614

Appeal identifier: 2009101010105

Request date: 20091104

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20091202

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20091202

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20091104

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090714

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070919

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100104

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20100203

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20100614

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20091209

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20100803

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20100803

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20130723

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20130723

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20140722

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20140722

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20150630

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20160630

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20160630

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20170704

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20170704

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20180628

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20200630

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20220622

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20230418

Termination category: Expiration of duration